Dentsply Sirona Tops Q2 EPS at $0.52 vs $0.36 Consensus and Affirms FY2026 Guidance
Question
Dentsply Sirona Tops Q2 EPS at $0.52 vs $0.36 Consensus and Affirms FY2026 Guidance
Direct answer
Adjusted Q2 EPS outperformance of 16 cents against consensus offsets top-line contraction of 4.1%, stabilizing XRAY valuation around affirmed $1.40-$1.50 full-year guidance. — bullish pressure on XRAY via operating margin resilience offsetting top-line revenue decline.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-09
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Dentsply Sirona Tops Q2 EPS at $0.52 vs $0.36 Consensus and Affirms FY2026 Guidance”, revision 1, evidence through 2026-09-09. https://marketontology.com/catalysts/2026-09-09/dentsply-sirona-tops-q2-eps-at-0-52-vs-0-36-consensus-and-affirms-fy2026-guidanc-ece24c
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| XRAY | ▲Bull | 1–5 days | operating margin resilience offsetting top-line revenue decline | 50 |
Dentsply Sirona Tops Q2 EPS at $0.52 vs $0.36 Consensus and Affirms FY2026 Guidance
Adjusted Q2 EPS outperformance of 16 cents against consensus offsets top-line contraction of 4.1%, stabilizing XRAY valuation around affirmed $1.40-$1.50 full-year guidance. — bullish pressure on XRAY via operating margin resilience offsetting top-line revenue decline.
Q2 adjusted EPS of $0.52 beat consensus of $0.36 with affirmed full-year EPS guidance of $1.40-$1.50.
- SourceQ2 adjusted EPS of $0.52 beat consensus of $0.36 with affirmed full-year EPS guidance of $1.40-$1.50.
- TransmissionAdjusted Q2 EPS outperformance of 16 cents against consensus offsets top-line contraction of 4.1%, stabilizing XRAY valuation around affirmed $1.40-$1.50 full-year guidance.
- SummaryDentsply Sirona delivered Q2 adjusted EPS of $0.52, beating consensus of $0.36. Revenue contracted 4.1% year-over-year despite 7.1% growth in Wellspect Healthcare. Management reaffirmed full-year 2026 revenue of $3.5B-$3.6B and EPS of $1.40-$1.50.
- XRAYDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- Sector rotation or peer guidance may override single-name reaction
- XRAY closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- XRAY price vs. pre-event level
- XRAY volume vs. 20-day average
- Sector ETF read-through
- Options implied volatility crush
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| XRAY | Bullishdisagreed | 10.72 2026-09-09 | -2.05% | -5.41% | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure · earnings_report · 2026-09-08
Related catalysts
- 2026-09-09Dentsply Sirona Beats Q2 EPS at $0.52 and Reaffirms FY26 Sales OutlookXRAY-5.41%
- 2026-09-09Dentsply Sirona Beats Q2 EPS at $0.52 and Affirms FY2026 Sales GuidanceALGN XRAY-5.41%
- 2026-09-09Dentsply Sirona reports Q2 adjusted EPS of $0.52 and maintains $3.5B-$3.6B sales outlookALGN XRAY-5.41%
- 2026-09-09Dentsply Sirona Tops Q2 EPS at $0.52 and Affirms Full-Year $3.5B-$3.6B Sales GuidanceXRAY-5.41%
- 2026-09-09Dentsply Sirona Beats Q2 Adjusted EPS Consensus at $0.52 and Reaffirms FY26 OutlookXRAY-5.41%
- 2026-09-09Dentsply Sirona Beats Q2 EPS at $0.52 and Affirms Full-Year 2026 GuidanceALGN XRAY-5.41%
- 2026-09-09Dentsply Sirona Beats Q2 EPS Estimates at $0.52 and Reaffirms FY2026 TargetsXRAY-5.41%
- 2026-09-09Dentsply Sirona Beats Q2 EPS at $0.52 vs $0.36 Consensus and Affirms FY26 OutlookALGN XRAY-5.41%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.